COSTEM 2019 | Lenalidomide: should maintenance therapy after autograft be limited?

Sergio Giralt

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, debates the utility, efficacy and limitation of maintenance therapy after autograft in multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video